Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Decheng Meng, Fengxia Zhang, Wenfei Yu, Xin Zhang, Guoliang Yin, Pengpeng Liang, Yanan Feng, Suwen Chen & Hongshuai Liu. (2023) Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver. Diabetes, Metabolic Syndrome and Obesity 16, pages 4043-4064.
Read now
Read now
Karolina Kujawowicz, Iwona Mirończuk-Chodakowska & Anna Maria Witkowska. (2023) Sirtuin 1 as a potential biomarker of undernutrition in the elderly: a narrative review. Critical Reviews in Food Science and Nutrition 0:0, pages 1-22.
Read now
Read now
Ramya Venkat, Elika Verma, Uzini Devi Daimary, Aviral Kumar, Sosmitha Girisa, Uma Dutta, Kwang Seok Ahn & Ajaikumar B. Kunnumakkara. (2023) The Journey of Resveratrol from Vineyards to Clinics. Cancer Investigation 41:2, pages 183-220.
Read now
Read now
Shifeng Fu, Meihong Yu, Yuyong Tan & Deliang Liu. (2021) Role of histone deacetylase on nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 15:4, pages 353-361.
Read now
Read now
. (2019) ALSUntangled no. 49: resveratrol. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:7-8, pages 619-624.
Read now
Read now
Articles from other publishers (58)
Hongshuai Liu, Yufei Li, Yan Jin, Xin Li, Dongxian Wang, Xiaowen Yu, Zhenyuan Jiang, Guoliang Yin, Suwen Chen, Xin Zhang, Decheng Meng, Wenfei Yu, Wenyin Jiang & Fengxia Zhang. (2024) Effects of different natural products in patients with non‐alcoholic fatty liver disease—A network meta‐analysis of randomized controlled trials. Phytotherapy Research 38:7, pages 3801-3824.
Crossref
Crossref
Kiana Mohammadian, Fatemeh Fakhar, Shayan Keramat & Agata Stanek. (2024) The Role of Antioxidants in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review. Antioxidants 13:7, pages 797.
Crossref
Crossref
Jingyi Ma, Dalton W. Staler & Ram I. Mahato. (2024) Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment. Medicinal Chemistry Research.
Crossref
Crossref
Rachakatla Anuradha, M. Srinivas, M. Satyavani, K. Suresh, MN. Muralidhar & Kalashikam Rajender Rao. (2024) Preconceptional paternal caloric restriction of high-fat diet-induced obesity in Wistar rats dysregulates the metabolism of their offspring via AMPK/SIRT1 pathway. Lipids in Health and Disease 23:1.
Crossref
Crossref
Zehuan Ding, Jian Zhang & Mahua Choudhury. (2024) A High-Fat and High-Fructose Diet Exacerbates Liver Dysfunction by Regulating Sirtuins in a Murine Model. Life 14:6, pages 729.
Crossref
Crossref
Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye & Bihui Zhong. (2024) Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials. Obesity Reviews 25:6.
Crossref
Crossref
Roghayeh Molani-Gol & Maryam Rafraf. (2024) Effects of resveratrol on the anthropometric indices and inflammatory markers: an umbrella meta-analysis. European Journal of Nutrition 63:4, pages 1023-1040.
Crossref
Crossref
Esma Oguz & Berna Karakoyun. (2024) Non-alcoholic fatty liver disease: pathogenesis and assessing the impact of dietary bioactive compounds on the liver. Marmara Medical Journal 37:2, pages 115-120.
Crossref
Crossref
Gislaine C. Batista-Jorge, Antônio S. Barcala-Jorge, Deborah F. Lelis, Daniel E. Santos, Antônio H. Jorge, Renato S. Monteiro-Junior & Sérgio H. S. Santos. (2024) Resveratrol Effects on Metabolic Syndrome Features: A Systematic Review and Meta-Analysis. Endocrines 5:2, pages 225-243.
Crossref
Crossref
Cheng Tian, Rongrong Huang & Ming Xiang. (2024) SIRT1: Harnessing multiple pathways to hinder NAFLD. Pharmacological Research 203, pages 107155.
Crossref
Crossref
Xinpeng Cong, Xi Zhu, Xiaogang Zhang & Zhongping Ning. (2024) Astragaloside IV inhibits angiotensin II-induced atrial fibrosis and atrial fibrillation by SIRT1/PGC-1α/FNDC5 pathway. Heliyon 10:10, pages e30984.
Crossref
Crossref
Kamila Kasprzak-Drozd, Przemysław Niziński, Paulina Kasprzak, Adrianna Kondracka, Tomasz Oniszczuk, Agata Rusinek & Anna Oniszczuk. (2024) Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?. International Journal of Molecular Sciences 25:7, pages 3746.
Crossref
Crossref
P. Ebrahimpour, M. Karamian & A. Sharifi. (2024) Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. Russian Journal of Gastroenterology, Hepatology, Coloproctology 34:1, pages 37-46.
Crossref
Crossref
Gladys Maribel Hidalgo-Lozada, Angelica Villarruel-López, Karla Nuño, Abel García-García, Yaír Adonaí Sánchez-Nuño & César Octavio Ramos-García. (2024) Clinically Effective Molecules of Natural Origin for Obesity Prevention or Treatment. International Journal of Molecular Sciences 25:5, pages 2671.
Crossref
Crossref
Karen Brown, Despoina Theofanous, Robert G. Britton, Grandezza Aburido, Coral Pepper, Shanthi Sri Undru & Lynne Howells. (2024) Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities. International Journal of Molecular Sciences 25:2, pages 747.
Crossref
Crossref
Ozra Tabatabaei-Malazy, Narges Lavari & Mohammad Abdollahi. 2024.
Qichao Hu, Wenwen Zhang, Feng Wei, Meilan Huang, Mengyao Shu, Dan Song, Jianxia Wen, Jundong Wang, Qing Nian, Xiao Ma, Jinhao Zeng & Yanling Zhao. (2023) Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization. Phytotherapy Research 38:1, pages 280-304.
Crossref
Crossref
Xuan He, Yubing Li, Xinyu Deng, Xiaolin Xiao & Jinhao Zeng. (2023) Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses. Frontiers in Pharmacology 14.
Crossref
Crossref
Jaime Zapata, Mauricio Castro-Sepulveda, Sandra Soto-Alarcon, Daniela Alvarez, Andres Bustamante, Guiselle Villarroel, Arturo Gallardo, Diego Fernando Garcia-Diaz, Rodrigo Valenzuela & Francisca Echeverria. (2023) Targeting Mitochondria for the Prevention and Treatment of Nonalcoholic
Fatty Liver Disease: Polyphenols as a Non-pharmacological
Approach. Current Medicinal Chemistry 30:26, pages 2977-2995.
Crossref
Crossref
Hang Huang, Yunmei Qiu, Anyang Tang, Wanzhi Li, Wanyi Yao, Mei Zhong, Ting Yang & Tangbin Zou. (2023) The impact of food restriction on liver enzyme levels: a systematic review and meta-analysis. Nutrition Reviews 81:8, pages 939-950.
Crossref
Crossref
Gustavo Henrique Ferreira Gonçalinho, Karen Lika Kuwabara, Nathalia Ferreira de Oliveira Faria, Marisa Fernandes da Silva Goes, Alessandra Roggerio, Solange Desirée Avakian, Célia Maria Cassaro Strunz & Antonio de Padua Mansur. (2023) Sirtuin 1 and Vascular Function in Healthy Women and Men: A Randomized Clinical Trial Comparing the Effects of Energy Restriction and Resveratrol. Nutrients 15:13, pages 2949.
Crossref
Crossref
Deng-Hua He, Yong-Zhan Zhang, Liang Xu, Ying Zhang, Jia-Jia Pei & Zhong-Fang Yan. (2023) Individualized intervention for patients with metabolic fatty liver disease based on Dietary Guidelines for Chinese Residents. World Chinese Journal of Digestology 31:8, pages 316-325.
Crossref
Crossref
Arefe Nemati, Zeinab Nikniaz & Ali Mota. (2023) Effects of Resveratrol Supplementation on Nonalcoholic Fatty Liver Disease Management. Topics in Clinical Nutrition 38:2, pages 144-160.
Crossref
Crossref
Yiping Li, Yang Liu, Zhiwei Chen, Kaiyue Tang, Lili Yang, Yuwei Jiang, Jue Wang, Ping Huang, Jianyi Wang, Peiyong Zheng & Haiyan Song. (2023) Protopanaxadiol ameliorates NAFLD by regulating hepatocyte lipid metabolism through AMPK/SIRT1 signaling pathway. Biomedicine & Pharmacotherapy 160, pages 114319.
Crossref
Crossref
Sepideh Soltani, Elham Sharifi‐Zahabi, Zohreh Sadat Sangsefidi, Azam Ahmadi Vasmehjani, Fatemeh Meshkini, Zachary Stephen Clayton & Shima Abdollahi. (2023)
The effect of resveratrol supplementation on biomarkers of liver health: A systematic review and
meta‐analysis
of randomized controlled trials
. Phytotherapy Research 37:3, pages 1153-1166.
Crossref
Crossref
Qi-Jun Wu, Tie-Ning Zhang, Huan-Huan Chen, Xue-Fei Yu, Jia-Le Lv, Yu-Yang Liu, Ya-Shu Liu, Gang Zheng, Jun-Qi Zhao, Yi-Fan Wei, Jing-Yi Guo, Fang-Hua Liu, Qing Chang, Yi-Xiao Zhang, Cai-Gang Liu & Yu-Hong Zhao. (2022) The sirtuin family in health and disease. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Xinyi Cao, Wang Liao, Hui Xia, Shaokang Wang & Guiju Sun. (2022) The Effect of Resveratrol on Blood Lipid Profile: A Dose-Response Meta-Analysis of Randomized Controlled Trials. Nutrients 14:18, pages 3755.
Crossref
Crossref
Kailin Yang, Junpeng Chen, Tianqing Zhang, Xiao Yuan, Anqi Ge, Shanshan Wang, Hao Xu, Liuting Zeng & Jinwen Ge. (2022) Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Frontiers in Immunology 13.
Crossref
Crossref
Mali Wu, Jie Zhang, Ran Gu, Fangfang Dai, Dongyong Yang, Yajing Zheng, Wei Tan, Yifan Jia, Bingshu Li & Yanxiang Cheng. (2022) The role of Sirtuin 1 in the pathophysiology of polycystic ovary syndrome. European Journal of Medical Research 27:1.
Crossref
Crossref
Shivani Khattar, Sauban Ahmed Khan, Syed Amir Azam Zaidi, Mahdi Darvishikolour, Uzma Farooq, Punnoth Poonkuzhi Naseef, Mohamed Saheer Kurunian, Mohammed Zaafar Khan, Athar Shamim, Mohd Masih Uzzaman Khan, Zeenat Iqbal & Mohd. Aamir Mirza. (2022) Resveratrol from Dietary Supplement to a Drug Candidate: An Assessment of Potential. Pharmaceuticals 15:8, pages 957.
Crossref
Crossref
Somayyeh Asghari, Mahsa Rezaei, Maryam Rafraf, Mahdiyeh Taghizadeh, Mohammad Asghari-Jafarabadi & Maryam Ebadi. (2022) Effects of Calorie Restricted Diet on Oxidative/Antioxidative Status Biomarkers and Serum Fibroblast Growth Factor 21 Levels in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Controlled Clinical Trial. Nutrients 14:12, pages 2509.
Crossref
Crossref
Qian Zhou, Yanmei Wang, Xuke Han, Shunlian Fu, Chan Zhu & Qiu Chen. (2022) Efficacy of Resveratrol Supplementation on Glucose and Lipid Metabolism: A Meta-Analysis and Systematic Review. Frontiers in Physiology 13.
Crossref
Crossref
Tao-tao Zhang, Yong Wang, Xiang-wen Zhang, Ke-yu Yang, Xiu-qin Miao & Guo-hua Zhao. (2022) MiR-200c-3p Regulates DUSP1/MAPK Pathway in the Nonalcoholic Fatty Liver After Laparoscopic Sleeve Gastrectomy. Frontiers in Endocrinology 13.
Crossref
Crossref
Cosmas Rinaldi A. Lesmana, Maria S. Paramitha & Irsan Hasan. 2022. Comprehensive Gut Microbiota. Comprehensive Gut Microbiota
475
488
.
E. A. Lyalyukova, I. V. Druk, I. V. Dolgalev, E. N. Chernysheva, E. N. Loginova & G. M. Konovalova. (2021) Diet therapy in patients with metabolically associated fatty liver disease: what is the choice for particular patient?. Experimental and Clinical Gastroenterology:10, pages 109-117.
Crossref
Crossref
Alyson M. Curry, Dawanna S. White, Dickson Donu & Yana Cen. (2021) Human Sirtuin Regulators: The “Success” Stories. Frontiers in Physiology 12.
Crossref
Crossref
Marziyeh Najafi, Omid Nikpayam, Omid Mohammad Tavakoli-Rouzbehani, Shahab Papi, Atefeh Amrollahi bioky, Elham sadat Ahmadiani & Golbon Sohrab. (2021) A comprehensive insight into the potential effects of resveratrol supplementation on SIRT-1: A systematic review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15:5, pages 102224.
Crossref
Crossref
Gabriela Macedo Fraiz, Aline Rosignoli da Conceição, Darlene Larissa de Souza Vilela, Daniela Mayumi Usuda Prado Rocha, Josefina Bressan & Helen Hermana Miranda Hermsdorff. (2021) Can resveratrol modulate sirtuins in obesity and related diseases? A systematic review of randomized controlled trials. European Journal of Nutrition 60:6, pages 2961-2977.
Crossref
Crossref
Elena Buzzetti, Audrey Linden, Lawrence MJ Best, Angela M Madden, Danielle Roberts, Thomas J G Chase, Suzanne C Freeman, Nicola J Cooper, Alex J Sutton, Dominic Fritche, Elisabeth Jane Milne, Kathy Wright, Chavdar S Pavlov, Brian R Davidson, Emmanuel Tsochatzis & Kurinchi Selvan Gurusamy. (2021) Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database of Systematic Reviews 2021:6.
Crossref
Crossref
Shiyao Zhang, Mengyi Xu, Wenxiang Zhang, Chang Liu & Siyu Chen. (2021) Natural Polyphenols in Metabolic Syndrome: Protective Mechanisms and Clinical Applications. International Journal of Molecular Sciences 22:11, pages 6110.
Crossref
Crossref
Mengyao Zhao, Shumin Chen, Xiaoguo Ji, Xin Shen, Jiangshan You, Xinyi Liang, Hao Yin & Liming Zhao. (2021) Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacological Research 166, pages 105517.
Crossref
Crossref
Jingwen Zhou, Yidi Chen, Jun Yu, Tianci Li, Ziyu Lu, Yan ChenXiaolong Zhang & Fang Ye. (2021) The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment. Medicine 100:12, pages e24884.
Crossref
Crossref
Mina Darand, Amirhosein Farrokhzad, Abed Ghavami, Amir Hadi, Elham Karimi, Abdulmnannan Fadel & Gholamreza Askari. (2020) Effects of resveratrol supplementation on liver enzymes: A systematic review and meta‐analysis of randomised controlled trials. International Journal of Clinical Practice 75:3.
Crossref
Crossref
Shumin Wei & Xiaoying Yu. (2021) Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Complementary Therapies in Medicine 57, pages 102635.
Crossref
Crossref
Sahar Rafiee, Hamed Mohammadi, Abed Ghavami, Erfan Sadeghi, Zahra Safari & Gholamreza Askari. (2021) Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. Complementary Therapies in Clinical Practice 42, pages 101281.
Crossref
Crossref
Beatriz Isabel García-Martínez, Mirna Ruiz-Ramos, José Pedraza-Chaverri, Edelmiro Santiago-Osorio & Víctor Manuel Mendoza-Núñez. (2021) Hypoglycemic Effect of Resveratrol: A Systematic Review and Meta-Analysis. Antioxidants 10:1, pages 69.
Crossref
Crossref
Luis E. Simental-Mendía, Claudia I. Gamboa-Gómez, Fernando Guerrero-Romero, Mario Simental-Mendía, Adriana Sánchez-García & Mariana Rodríguez-Ramírez. 2021. Pharmacological Properties of Plant-Derived Natural Products and Implications for Human Health. Pharmacological Properties of Plant-Derived Natural Products and Implications for Human Health
257
272
.
Nikolaos Perakakis, Konstantinos Stefanakis & Christos S. Mantzoros. (2020) The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 111, pages 154320.
Crossref
Crossref
Karolina Jakubczyk, Karolina Skonieczna-Żydecka, Justyna Kałduńska, Ewa Stachowska, Izabela Gutowska & Katarzyna Janda. (2020) Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease—A Meta-Analysis. Nutrients 12:8, pages 2435.
Crossref
Crossref
Jiezhong Chen & Luis Vitetta. (2020) Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. International Journal of Molecular Sciences 21:15, pages 5214.
Crossref
Crossref
Dong Zhang, Bo Li, Bin Li & Yue Tang. (2020) Regulation of left atrial fibrosis induced by mitral regurgitation by SIRT1. Scientific Reports 10:1.
Crossref
Crossref
Xiao Meng, Jing Zhou, Cai-Ning Zhao, Ren-You Gan & Hua-Bin Li. (2020) Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review. Foods 9:3, pages 340.
Crossref
Crossref
Samaneh Hosseinabadi, Maryam Rafraf, Somayyeh Asghari, Mohammad Asghari-Jafarabadi & Shohreh Vojouhi. (2020) Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Complementary Therapies in Medicine 49, pages 102290.
Crossref
Crossref
Dimitrios A. Koutoukidis, Nerys M. Astbury, Kate E. Tudor, Elizabeth Morris, John A. Henry, Michaela Noreik, Susan A. Jebb & Paul Aveyard. (2019) Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease. JAMA Internal Medicine 179:9, pages 1262.
Crossref
Crossref
Sedigheh Asgary, Raheleh Karimi, Saeideh Momtaz, Rozita Naseri & Mohammad Hosein Farzaei. (2019) Effect of resveratrol on metabolic syndrome components: A systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders 20:2, pages 173-186.
Crossref
Crossref
S. M. Mousavi, A. Milajerdi, A. Sheikhi, H. Kord‐Varkaneh, C. Feinle‐Bisset, B. Larijani & A. Esmaillzadeh. (2018) Resveratrol supplementation significantly influences obesity measures: a systematic review and dose–response meta‐analysis of randomized controlled trials. Obesity Reviews 20:3, pages 487-498.
Crossref
Crossref
Brandon J. Perumpail, Andrew A. Li, Umair Iqbal, Sandy Sallam, Neha D. Shah, Waiyee Kwong, George Cholankeril, Donghee Kim & Aijaz Ahmed. (2018) Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD. Diseases 6:3, pages 80.
Crossref
Crossref
Shinsuke Nirengi, Mami Fujibayashi, Sachiko Furuno, Akihiko Uchibe, Yasuharu Kawase, Shin Sukino, Yaeko Kawaguchi, Satomi Minato, Kazuhiko Kotani & Naoki Sakane. (2018) Nonalcoholic Fatty Liver Disease in University Rugby Football Players. Frontiers in Endocrinology 9.
Crossref
Crossref